Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients

• Príomhchruthaitheoirí: Francesca Barei (Údar), Martina Zussino (Údar), Simona Tavecchio (Údar), Luisa Angileri (Údar), Arianna Rizzo (Údar), Paolo Calzari (Údar), Angelo V. Marzano (Údar), Silvia Ferrucci (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2024-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Background: The main objective was to analyze patient-reported outcomes (PRO) trends over a four-year period in severe atopic dermatitis (AD) patients treated with dupilumab. Methods: data from 126 severe patients receiving dupilumab for at least 48 months were collected. The clinical scores assesse...